Akebia Therapeutics Inc (NASDAQ: AKBA) kicked off on Tuesday, down -1.42% from the previous trading day, before settling in for the closing price of $2.12. Over the past 52 weeks, AKBA has traded in a range of $1.52-$4.08.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 32.58%. While this was happening, its average annual earnings per share was recorded 105.24%. With a float of $254.74 million, this company’s outstanding shares have now reached $263.04 million.
Akebia Therapeutics Inc (AKBA) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Akebia Therapeutics Inc is 3.92%, while institutional ownership is 41.75%. The most recent insider transaction that took place on Jun 30 ’25, was worth 151,622. In this transaction SVP, CFO, CBO & Treasurer of this company sold 41,314 shares at a rate of $3.67, taking the stock ownership to the 503,586 shares. Before that another transaction happened on Jun 30 ’25, when Company’s Officer proposed sale 41,314 for $3.67, making the entire transaction worth $151,622.
Akebia Therapeutics Inc (AKBA) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.1 earnings per share (EPS), lower than consensus estimate (set at -0.05) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Take a look at Akebia Therapeutics Inc’s (AKBA) current performance indicators. Last quarter, stock had a quick ratio of 1.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.17, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach 0.16 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
The latest stats from [Akebia Therapeutics Inc, AKBA] show that its last 5-days average volume of 10.15 million was superior to 4.1 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 6.61%.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 1.24%, which indicates a significant decrease from 2.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.17 in the past 14 days, which was higher than the 0.15 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.85, while its 200-day Moving Average is $2.77. Now, the first resistance to watch is $2.13. This is followed by the second major resistance level at $2.18. The third major resistance level sits at $2.21. If the price goes on to break the first support level at $2.06, it is likely to go to the next support level at $2.03. The third support level lies at $1.98 if the price breaches the second support level.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
The company with the Market Capitalisation of 554.16 million has total of 265,145K Shares Outstanding. Its annual sales at the moment are 160,180 K in contrast with the sum of -69,410 K annual income. Company’s last quarter sales were recorded 62,470 K and last quarter income was 250 K.
